Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Oct 28;6(4):79-81.
doi: 10.1002/cld.506. eCollection 2015 Oct.

Treatment of patients with hepatitis C virus genotype 3: Where are we now?

Carmen Landaverde  1 , Jennifer T Wells  1 , Julio Gutierrez  1 , Fred Poordad  1
Affiliations
Review

Treatment of patients with hepatitis C virus genotype 3: Where are we now?

Carmen Landaverde et al. Clin Liver Dis (Hoboken). .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
SVR12 in HCV GT 3 patients with cirrhosis by treatment history (adapted from Foster et al4). Abbreviations: PEG, pegylated interferon; RBV, ribavirin; SOF, sofosbuvir; SVR, sustained virological response; TE, treatment‐experienced; TN, treatment‐naive.
See this image and copyright information in PMC

References

    1. Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta‐analysis. J Hepatol 2009;50:1142‐1154. - PubMed
    1. Kanwal F, Kramer JR, Ilyas J, Duan Z, El‐Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology 2014;60:98‐105. - PMC - PubMed
    1. American Association for the Study of Liver Diseases/Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. Initial treatment box. Summary of recommendations for patients who are initiating therapy for HCV infection by HCV genotype. Available at: http://www.hcvguidelines.org/full-report/initial-treatment-box-summary-r.... Accessed September 24, 2015.
    1. Foster GR, Pianko S, Cooper C, Brown A, Forton D, Nahass RG, et al. Sofosbuvir plus Peg‐IFN/RBV for 12 weeks vs sofosbuvir/RBV for 16 or 24 weeks in genotype 3 HCV‐infected patients and treatment‐experienced cirrhotic patients with genotype 2 HCV: The BOSON Study [Abstract L05]. J Hepatol 2015;62(suppl):S259.
    1. Lawitz E, Flamm S, Yang JC, Phillip S. Pang PS, Zhu Y, et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir‐based regimens with ledipasvir/sofosbuvir for 24 weeks [Abstract O005]. J Hepatol 2015;62(suppl):S192.